Aristotle University Of Thessaloniki (AUTH)
Βελτίωση της σχετιζόμενης με την παχυσαρκία νοσηρότητας μετά απώλεια βάρους με ενδογαστρικό ασκό
Abstract
dc:descriptionObesity involves excessive increase of body weight and fatty mass, as an interaction between huge intake, inefficient calorie utilization and reduced metabolic and physical activity. It is now considered the most common chronic physical illness in modern society, most often associated with increased morbidity and mortality, and a risk factor for an array of other diseases, including mental disorders. The purpose of this prospective epidemiologic study was to record the co-morbidities presented in a cohort of obese patients, referred for intragastric balloon placement for weight loss, and to follow-up their 6-month outcome in relation to weight loss achievement. One hundred consecutive females fulfilling criteria for intragastric balloon [BioEnterics Intragastric Balloon, Allergan®, Marlow International, UK] treatment were assessed: demographic data, anthropometric measures, and co-morbidities - diabetes, hypertension, joint disease, GERD, dyslipidaemia, sleep apnoea - were recorded only in the cases where medicines were being taken to treat. Moreover, depression status was assessed by the well recognized psychological measure, the Beck’s Depression Inventory. The same data were recorded mid-period, and at 6-months, at the time of balloon removal. All females had an age of 36.25±11.75 years and a minimum of one [maximum more than 3] co-morbidities. Anthropometric data were as follows: body weight 123.89±29.64kg, ΒΜΙ 42.95±8.83, % body fat 47±6.36%, RMR 1874.24±497.97kcal. Psychometric testing revealed 65 out of 100 patients to be suffering from depression, the 26 [40%] being mildly, the 21 [32.3%] moderately and the 18 [27.7%] severely depressed. Six months thereafter, at time of balloon removal, individuals experienced a significant % reduction of co-morbidities, namely joint disease by 90%, GERD by 73%, dyslipidaemia by 52%, diabetes mellitus by 48%, respiratory/sleep apnoea by 45%, and hypertension by 39%, the reduction defined as no more need for medication. In respect to anthropometric data, all were also found significantly reduced; body weight was 103.67±28.02kg, ΒΜΙ 35.89±8.53kg/m2, % body fat 41.02±7.24, and RMR 1727±475.83kcal. The 65 depressed females experienced a striking improvement in depression status, namely the rates of mild, moderate and severe depression improved from 40%, 32.3% and 27.7% to 20%, 7.7% and 1.5% respectively, with 70.8% of initially obese finally exhibiting no depression at all. Moreover, analysis of their data reveals that the range of BMI neither affects the depression score nor the rate of reduction of obesity parameters. However, there was a significant weight loss difference [%EWL>30] in favour of those who were less severely depressed initially. In conclusion, the degree of weight loss observed in obese individuals treated with an intragastric balloon was found to positively affect all obesity-related parameters, including both co-morbidities and depression status.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2013
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Deliopoulou, Kyriaki
- Ντελιοπούλου, Κυριακή
Subjects
dc:subject × 16Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/36777